Jeanette Boudreau

Voluntary training in mice and submandibular lymphocyte response to acute exercise.

Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.

Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Potentiating cancer immunotherapy using an oncolytic virus.

CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells.

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.

Engineering dendritic cells to enhance cancer immunotherapy.